



Physician Sample Request Form

Print Physician Sample Request Form

Fax Form To: 1-866-635-5312

**Mail Form To: Attn: Ther-Rx Corporation
One Phoenix Drive
Lincoln Park, NJ 07035-9960**

Form must be signed, dated, and state license number included.
Mailed form must have the original signature of practitioner listed on the form.



4 Samples of Evamist®
(estradiol transdermal spray) 8.1 ml

Please Complete the Fields Below

Licensed Practitioner's Name **(Required)**: Last: _____

(Required): First: _____

Professional Designation **(Required)**:

MD DO NP PA CNM (Please check the appropriate box)

(Required)

Office Address: _____

City: _____ State: _____ Zip Code: _____

Phone : _____ Fax : _____

State License # **(Required)**: _____

I am requesting these samples from Ther-Rx Corporation for the medical needs of my patients. My signature certifies that I am a licensed practitioner eligible to receive these samples. These samples are prohibited from resale, trade or barter and will not be returned for credit.

Licensed Practitioner's

Signature: **(Required)**† **X** _____

(STAMPED SIGNATURES NOT ACCEPTED)

*As a Nurse Practitioner, I attest that I have met all appropriate state-level sampling conditions, including but not limited to collaborative or supervisory agreements with a physician.

†In accordance with individual state law regarding your professional designation.

Today's Date:

Month/Day/Year **(Required)** **X** _____ / _____ / _____

In compliance with "Prescription Drug Marketing Act" regulations, only sample requests that are signed, dated and include State License numbers will be processed.

*Evamist is manufactured by: DPT Labs.-San Antonio, TX, for Ther-Rx Corp., Bridgeton, MO 63044, (314) 646-3700
Evamist samples distributed by Phoenix Marketing Group, LLC, One Phoenix Dr., Lincoln Park, NJ 07035*

**Evamist is indicated for the treatment of moderate-to-severe vasomotor symptoms due to menopause.
Please see reverse side for important safety information.
Please [click here](#) for full Prescribing information for Evamist.**

Important safety information about Evamist®

Evamist is indicated for the treatment of moderate-to-severe vasomotor symptoms due to menopause.

WARNING—ENDOMETRIAL CANCER, CARDIOVASCULAR, AND OTHER RISKS

ENDOMETRIAL CANCER Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding.

CARDIOVASCULAR AND OTHER RISKS Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 6.8 years and 7.1 years, respectively, of treatment with daily oral conjugated estrogens (CE 0.625 mg), relative to placebo. The estrogen plus progestin WHI substudy reported increased risk of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and DVT in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE 0.625 mg combined with medroxyprogesterone acetate (MPA 2.5 mg), relative to placebo. The Women's Health Initiative Memory Study (WHIMS), a substudy of the WHI, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE 0.625 mg alone and during 4 years of treatment with daily CE 0.625 mg combined with MPA 2.5 mg, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women. In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA and other combinations and dosage forms of estrogens and progestins. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

Evamist should not be used in women with undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active deep vein thrombosis, pulmonary embolism, or history of these conditions; active or recent arterial thromboembolic disease; liver dysfunction or disease; or known or suspected pregnancy.

In a clinical trial with Evamist, the most common side effects were headache, breast tenderness, nasopharyngitis, nipple pain, back pain, nausea, and arthralgia.

For more information about Evamist, visit www.evamist.com or call 877-567-7676.